NCT03065621View on ClinicalTrials.gov

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

March 28, 2019

Study Completion Date

February 1, 2023

Conditions
Breast Cancer Female
Interventions
DRUG

Palbociclib

Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.

Trial Locations (5)

1070

Institut Jules Bordet, Anderlecht

1090

CHU Brugmann, Brussels

1200

CHU Saint-Luc, Brussels

3000

UZ Leuven Gasthuisberg, Leuven

5000

CHU UCL Namur Sainte-Elisabeth, Namur

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER

NCT03065621 - Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) | Biotech Hunter | Biotech Hunter